Navigation Links
Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
Date:12/12/2008

irin is genotoxic and mutagenic and should be considered a potential carcinogen.

Contraindications

PEGINTRON is contraindicated in patients with known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. PEGINTRON/REBETOL combination therapy is additionally contraindicated in women who are pregnant or may become pregnant (see Boxed Warning and Pregnancy section), men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL per min.

Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. If this drug is used during pregnancy or if a patient becomes pregnant, the patient should be apprised of the potential hazard to a fetus. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

Most common adverse reactions (more t
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Aquarium Research Institute (MBARI) have observed a deep-sea octopus ... than any other known animal. Throughout this time, the ... predators. This amazing feat represents an evolutionary balancing act ... plenty of time to develop within their eggs, and ... or no food. , Every few months for the ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... who were breastfed for three months or more ... chronic inflammation associated with cardiovascular and metabolic diseases, ... Washington University in St. Louis. , "This study ... for children,s health decades later," said Molly W. ... and a co-author of the study with Thomas ...
(Date:7/30/2014)... ‚ÄúToday, we have said ¡Basta! (enough) to the ... to our children and our families. The SWEET Act ... to put the health of people first and make ... President and CEO of the National Alliance for Hispanic ... (SWEET) Act by Congresswoman Rosa L. DeLauro. , The ...
(Date:7/30/2014)... With the recent May 21st opening of the ... Museum Workshop in the Meatpacking District has been encountering some ... Carole Barnes, "We have had to re-write the description of ... who sell us so tourists don't confuse the two 9/11 ... we do and what the new Museum does in terms ...
Breaking Medicine News(10 mins):Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5
... the Division of Allergy and Immunology at Cincinnati ... extend funding of his long-standing investigation into "Regulation ... award from the National Institute of Allergy and ... of research accomplishment." Eosinophilic disorders occur ...
... HealthDay Reporter , THURSDAY, July 22 (HealthDay News) ... a result of taking statins don,t seem to benefit from ... The conventional wisdom has been that to reduce the ... LDL, or "bad," cholesterol and increase your HDL, or ...
... specific brain regions in female patients with irritable bowel syndrome ... abdomen, along with diarrhea, constipation or both. ... the study appears in the July issue of the journal ... IBS is associated with both decreases and increases in grey ...
... include certain must-have vitamins in their diets to stave off ... Alberta. , A study of 43 children and teens ... disease showed that they also tended to have low bone ... and minerals. That means they should be getting more of ...
... study into the causes of deaths of workers at ... rates from all causes and cancer in general when ... known by occupational health researchers as the "healthy worker ... such as leukemia or multiple myeloma were slightly above ...
... total joint replacement registry based on carefully designed and ... cost-effectiveness and research, according to a paper published in ... and Related Research , a journal of the Association ... Total Joint Replacement Registry the nation,s largest such registry ...
Cached Medicine News:Health News:Doctor at Cincinnati Children's receives prestigious NIH MERIT Award 2Health News:Some on Statins May Not Need Boost in 'Good' Cholesterol 2Health News:Some on Statins May Not Need Boost in 'Good' Cholesterol 3Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 3Health News:Study describes health effects of occupational exposures in Paducah Gaseous Diffusion Plant workers 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , , SAN DIEGO , Jan. 15 ... entry of a settlement agreement which will resolve the consolidated securities ... Master File No: 3:09-cv-00921-LAB-WMC. The defendants have agreed to pay ... the company has agreed to issue to the plaintiffs, class a ...
... , , , , , , ... Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... a,leading fully integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has relocated its headquarters to its new buildings,in ...
Cached Medicine Technology:Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 2Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 3Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 4China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 2China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 3
... High Productivity, improved safety and lower cost per ... solution to sample prep bottlenecks in the busy ... amazingly compact and quiet centrifuge spins standard 5 ... yet it produces quality serum or plasma equal ...
The StatSpin Express 3 provides faster turnaround time and greater productivity for your laboratory....
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: